Current treatments of chronic immune-mediated demyelinating polyneuropathies.
about
Vitamin D, cognition, and dementia: A systematic review and meta-analysisPlasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyPlasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.Peripheral neuropathies in rheumatic disease--a guide to diagnosis.Neuromuscular ultrasound in polyneuropathies and motor neuron disease.Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.Ultrasonography in the diagnosis of peripheral nerve disease.A patient with amyotrophic lateral sclerosis and atypical clinical and electrodiagnostic features: a case report.Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.Intravenous immunoglobulin for treatment of neuromuscular disease.Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.Peripheral Neuropathy
P2860
Q22306178-B9167306-D7CE-4F6A-A59E-016F6CE4E784Q24187755-9E992A06-B9FA-46AD-9E11-08B54134BA3EQ24200900-78643EEF-90D8-4151-BEA9-344C3BEC0F13Q30276550-E6EFF4A9-13C8-446F-B40E-A5D0A197809FQ34072287-E4EA2951-5E23-4FBC-9D6A-E68BDD7A771FQ34122035-3A75E461-89D0-4B5B-8D13-EF0A3287D5F2Q37789530-D16F38F9-1308-48A1-B3F1-E97FCEDC2397Q38036106-F39474D7-88CD-4E66-B714-122BFB0A2241Q38102947-05015349-371A-43A8-9083-83E27425EA19Q38711142-E6850637-3985-4A3A-AE15-B0031E672A7DQ39453512-A92C6E40-FE79-4C9B-BF1D-0179784B7A08Q39870298-DC9C0D0A-7A6B-46D7-8F73-D962073FDD97Q40444924-EA3BA6EC-182A-4583-B3F4-7A19ADCA5426Q43074735-D7843211-B6F9-4C1F-AFE1-0255D921EB75Q43678458-30C38FAF-2320-4124-8D38-79CD4D1A2C55Q47584292-13C51FA2-CA27-4B45-88F5-991251D36D70Q50133537-3C15BDAD-9B3C-4E7C-9837-224257B30004Q51101355-52ACEB96-3802-45FB-8452-5C854F6A701FQ56385011-3FF05DF1-BD2B-4860-90E2-1B56872BF18F
P2860
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@en
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@nl
type
label
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@en
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@nl
prefLabel
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@en
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@nl
P2860
P356
P1433
P1476
Current treatments of chronic immune-mediated demyelinating polyneuropathies.
@en
P2093
Thomas H Brannagan
P2860
P304
P356
10.1002/MUS.21277
P577
2009-05-01T00:00:00Z